U.S. FDA grants breakthrough designation to Datar’s blood test to detect breast cancer
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
Subscribe To Our Newsletter & Stay Updated